Phesgo Approval; PC Guideline; ESMO GIJuly 06, 2020 | Oncology Internal Medicine FDA Approves Phesgo, At-home Treatment Regimen for Breast Cancer According to the FDA, Phesgo — the combination of pertuzumab, trastuzumab and hyaluronidase-zzxf – is initially used in combination with chemotherapy and then can be administered subcutaneously at home by a health care professional after completion of chemotherapy. Read full article Geriatrics AUA, ASTRO, and SUO Release Consensus Guideline on Advanced Prostate Cancer Published on the AUA website and developed by a panel of experts from these three groups as well as representation from the American Society of Clinical Oncology (ASCO) and a patient advocate, 38 recommendations are listed across the care continuum of advanced disease. Read full article Gastroenterology First-Line NALIRIFOX Shows Promising Antitumor Activity in Locally Advanced/Metastatic PDAC In this podcast from the virtual 2020 ESMO World Congress on Gastrointestinal Cancer, Dr. Zev Wainberg discusses emerging data from the phase 1/2 trial of first-line liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin for pancreatic ductal adenocarcinoma (PDAC). Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS